A detailed history of Parallel Advisors, LLC transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 21 shares of KYMR stock, worth $853. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21
Previous 8 162.5%
Holding current value
$853
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$30.16 - $52.4 $392 - $681
13 Added 162.5%
21 $0
Q4 2023

Feb 09, 2024

BUY
$10.97 - $26.84 $87 - $214
8 New
8 $0
Q1 2022

Apr 28, 2022

SELL
$35.3 - $64.68 $741 - $1,358
-21 Closed
0 $0
Q4 2021

Jan 20, 2022

SELL
$49.91 - $65.56 $32,441 - $42,614
-650 Reduced 96.87%
21 $1,000
Q3 2021

Nov 02, 2021

BUY
$47.8 - $66.66 $31,069 - $43,329
650 Added 3095.24%
671 $39,000
Q2 2021

Aug 06, 2021

BUY
$31.08 - $51.95 $652 - $1,090
21 New
21 $1,000

Others Institutions Holding KYMR

About Kymera Therapeutics, Inc.


  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $2.22B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.